Abstract:Introduction. The increasing prevalence and growing resistance of fungi present a significant peril to public health. There are only four classes of antifungal medicines available today, and few candidates are in clinical trials. Hypothesis/Gap Statement. Rapid and sensitive diagnostic techniques are lacking for most fungal pathogens, and those that do exist are expensive or hard to obtain. Aim. This study aimed to evaluate the feasibility of a novel automated antifungal susceptibility testing system, Fungus AST, in comparison to the broth microdilution method (BMD) recommended by the Clinical and Laboratory Standards Institute (CLSI). Methodology. A total of 101 clinical Candida spp. isolates were collected from the Zengcheng Branch of Nanfang Hospital and subjected to antifungal susceptibility testing. Antifungal susceptibility was assessed using the Fungus AST method and the BMD. Results. In this study, we introduce a novel automated antifungal susceptibility testing system, Fungus AST, which detects the turbidity and/or colour intensity of microdilution wells using a four-wavelength detection technology in real time and is designed to match the growth characteristics of strains over time. Based on our analysis, all reportable ranges of Fungus AST were suitable for clinical fungal isolates in PR China. Within ±twofold dilutions, reproducibility was 100 %. Considering the BMD as a referenced method, ten antifungal agents (anidulafungin, caspofungin, micafungin, fluconazole, voriconazole, posaconazole, itraconazole, amphotericin B, 5-flucytosine and nystatin) showed an essential agreement of >95 %. The category agreement of five antifungal agents (anidulafungin, caspofungin, micafungin, fluconazole and voriconazole) was excellent at >90 %. One Candida albicans isolate and voriconazole showed a major error (ME) (1.7 %), and no other ME or very ME agents were found. Conclusion. Given the above, it can be argued that the utilization of Fungus AST is a discretionary automated approach. More improvements are needed in Fungus AST compared to the BMD system for a wider range of clinical isolates, including different types of fungi.

Comparative evaluation of ATB FUNGUS 2 procedure and CLSI M27-A2 broth microdilution method for antifungal susceptibility testing of Candida species and Cryptococcus neoformans

Comparative Evaluation of ATB FUNGUS 3 Procedure and CLSI M27-A2 Broth Microdilution Method for Antifungal Susceptibility Testing of Pathogenic Yeasts

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Evaluation of different tigecycline susceptibility testing methods for Acinetobacter baumannii

Comparison of susceptibility testing by EUCAST and CLSI broth microdilution methods against Aspergillus isolates

Antifungal Susceptibility Testing of 100 Clinical Isolates of Pathogenic Yeasts

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

Novel automated antifungal susceptibility testing system for yeasts based on dual-detection algorithm of turbidimetry and colorimetry

Assaying the Susceptibility of Fluconazole-Resistant Candida Albicans to Common Antifungal Drugs

Categorizing Susceptibility of Clinical Isolates of Candida auris to Amphotericin B, Caspofungin, and Fluconazole by Use of the CLSI M44-A2 Disk Diffusion Method

Standardisation of high throughput microdilution antifungal susceptibility testing for Candida albicans and Cryptococcus neoformans

In-vitro susceptibility of 248 isolates of Candida sp. and Cryptococcus neoformans to four antifungal agents

Evaluation of the Vitek 2 system for antifungal susceptibility testing of Candida auris using a representative international panel of clinical isolates: overestimation of amphotericin B resistance and underestimation of fluconazole resistance

Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time

Determination of amphotericin B antifungal susceptibility in Candida strains using an inverted microscope

In-vitro Susceptibility of Cryptococcus Neoformans and Candida Species to Five Antifungal Drugs

Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest

Comparison of A Glucose Consumption Based Method with the Clsi M38-A Method for Testing Antifungal Susceptibility of Trichophyton Rubrum and Trichophyton Mentagrophytes

Antifungal susceptibilities of 44 isolates of Trichophyton mentagrophytes isolates evaluated with CLSI M38-A2 scheme

Comparison of Six Antifungal Susceptibilities of 11 Candida Species Using the VITEK2 AST–YS08 Card and Broth Microdilution Method

Antifungal Susceptibility Testing of Clinical Isolates of Candida Albicans to Terbinafine, Miconazole and Nystatin